3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Leukemia, Myeloid, Acute
44
Precursor Cell Lymphoblastic Leukemia-Lymphoma
32
Myelodysplastic Syndromes
25
Recurrence
18
Multiple Myeloma
17
Lymphoma, Non-Hodgkin
14
Lymphoma, B-Cell
14
Lymphoma
14
Leukemia, Lymphocytic, Chronic, B-Cell
13
Ovarian Neoplasms
12
Hematologic Neoplasms
12
Pancreatic Neoplasms
10
Melanoma
10
Leukemia
9
Hodgkin Disease
9
Burkitt Lymphoma
9
Stomach Neoplasms
8
Myeloproliferative Disorders
8
Lymphoma, Large B-Cell, Diffuse
8
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
8
Neoplasms
7
Leukemia, Biphenotypic, Acute
7
Colorectal Neoplasms
7
Triple Negative Breast Neoplasms
6
Neoplasm Metastasis
6
Lymphoma, Mantle-Cell
6
Lymphoma, Follicular
6
Leukemia, Myelomonocytic, Juvenile
6
Leukemia, Myelomonocytic, Chronic
6
Breast Neoplasms
6
Interventions
cabozantinib
5
Nivolumab
4
Ipilimumab
4
Axitinib
4
pembrolizumab
3
Blood Specimen Collection
3
zimberelimab
2
atezolizumab
2
Surveys and Questionnaires
2
Sunitinib
2
Irinotecan
2
temsirolimus
1
spartalizumab
1
salicylhydroxamic acid
1
palbociclib
1
orellanine
1
olaparib
1
liposomal doxorubicin
1
lenvatinib
1
gallium Ga 68 dotatate
1
fludarabine
1
brodalumab
1
belzutifan
1
aldesleukin
1
adagrasib
1
Vincristine
1
Temozolomide
1
Taxes
1
Selenomethionine
1
Ropivacaine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Kidney Neoplasms
×
fludarabine
×
90 days
×
Clear all
NCT07551349
2026-04-24
DUAL-NK RCC
Beijing Biotech
Phase 1/2
Recruiting
36 enrolled